Sharing and describing experimental results unambiguously with sufficient detail to enable replication of results is a fundamental tenet of scientific research. In today's cluttered world of ''-omics'' sciences, data standards and standardized use of terminologies and ontologies for biomedical informatics play an important role in reporting high-throughput experiment results in formats that can be interpreted by both researchers and analytical tools. Increasing adoption of Semantic Web and Linked Data technologies for the integration of heterogeneous and distributed health care and life sciences (HCLSs) datasets has made the reuse of standards even more pressing; dynamic semantic query federation can be used for integrative bioinformatics when ontologies and identifiers are reused across data instances. We present here a methodology to integrate the results and experimental context of three different representations of microarray-based transcriptomic experiments: the Gene Expression Atlas, the W3C BioRDF task force approach to reporting Provenance of Microarray Experiments, and the HSCI blood genomics project. Our approach does not attempt to improve the expressivity of existing standards for genomics but, instead, to enable integration of existing datasets published from microarray-based transcriptomic experiments. SPARQL Construct is used to create a posteriori mappings of concepts and properties and linking rules that match entities based on query constraints. We discuss how our integrative approach can encourage reuse of the Experimental Factor Ontology (EFO) and the Ontology for Biomedical Investigations (OBIs) for the reporting of experimental context and results of gene expression studies.
Introduction
Personalized genomic information is becoming increasingly relevant for targeted therapy strategies such as pharmacogenomics [1] . The US Food and Drug Administration (FDA), for example, is now requesting genetic testing to determine the applicability of certain drugs [2] . The falling prices of high-throughput technologies such as microarrays, next generation sequencing (NGS) and mass spectrometry are also enabling genetic testing on a much larger scale by enabling the simultaneous measurement of thousands of genes/proteins in a single high-throughput analysis. Making full use of this data for targeted therapy requires (1) standardization of data collection and analysis in order to ensure that results can be replicated; (2) shared and integrated experimental results across multiple institutions so that genetic cohorts of patients can be assembled; and (3) the ability to identify, among hundreds of differentially expressed genes, a small list of genes that can be targeted for genetic testing and targeted treatment.
Standards for genomics: proposed and in practice
Standardization is tied directly to the legacy value of highthroughput experimental results as it ensures that the methodologies and experimental context used to produce a dataset are described unambiguously and with sufficient detail to enable other scientists to replicate its results [3, 4] . It is only when experimental results can be accurately replicated and linked to phenotypical information that discoveries can be translated into a clinical scenario to improve decision making [5] . Furthermore, reuse of standards when linking high-throughput experimental results to phenotypes can be essential for making use of biological resources such as tissue banks [6] and for linking across several ''-omic'' sciences.
Standardization efforts and the creation of guidelines have been under way for recording and sharing many aspects of functional genomics experiments related to its experimental context. Once a standard for representing experimental biological data becomes widely used by the communities involved in generating and using the data, it can be reliably applied in tool development and data sharing. The Minimum Information about a Microarray Experiment (MIAME) [3] , for example, is a widely used guideline, created by the microarray community for describing a microarray experiment. MIAME has gained momentum when journals began, in 2002, requesting gene expression experiments to be MIAME-compliant before publication. The Microarray and Gene Expression (MAGE) Object Model began development shortly after MIAME and a mapping to an XML format was created, MAGE-ML, to capture requirements of the MIAME guideline [7] . Several other guidelines and standard formats for ''omics'' results have been developed since: in specific contexts, such as RNAi screening experiments, the Minimum Information About an RNAi Experiment guidelines [8] have been issued to incorporate information about experimental context. In order to promote cross talk between individual guideline checklists and modular reuse, Minimum Information for Biological and Biomedical Investigations started compiling proposed guidelines for reporting experimental results in biosciences [4] .
Standards can also become a powerful enabler for data integration: once a standardized model for representing experimental ''omics'' data becomes widely used and accepted by the communities involved in generating and sharing the data, the syntactic barrier that prevents multiple source datasets from being merged is eliminated. Studies and approaches to integrating experimental results from several other ''-omics'' sciences such as genomics and proteomics have also relied on reusing standards [9, 10] .
Experimental results from ''-omics'' sciences, however, are difficult to standardize. One of the reasons causing this has been that changes in technologies over the years have brought multiple methods for measuring altered gene expression -from different cDNA microarrays platforms to the different next generation sequencing platforms. In fact, Genomic Technologies and Biotechnology seems to be advancing more rapidly than our ability to standardize its methods and results.
The ''sticking point'' for standards: tools and databases implementing standards
To achieve wide acceptance, standards and guidelines must successfully describe the requirements in terms that the final users (i.e. the biology domain experts generating the data) can use and understand [11] . However, their usability is limited without the appropriate tools to produce and manipulate the metadata structure. For example, insufficient tool support, such as a lack of simple user interfaces, has made it impractical to apply MAGE-ML in the daily practice of most wet lab scientists. These conditions led to the creation of MAGE-TAB [12] , a simpler spread-sheet based format for reporting microarray experimental context, developed by reusing standards-compliant tools (Perl packages [13] , Annotare [14] ). This has further boosted the popularity and acceptance of MIAME as a standard and three large microarray databases have since integrated the MIAME guideline in their repositories: ArrayExpress from the European Bioinformatics Institute (EBI) [15] , which relies on MAGE-TAB format to help provide consistent syntactic support; the Gene Expression Omnibus (GEO) from the National Institutes of Health [16] which makes use of the MIAME notation in Markup Language [17] and the Simple Omnibus Format in Text [18] as alternatives to structure similar information; and the Center for Information Biology gene Expression database [19] , also using MAGE compliant formats. Data integration across databases is somewhat enabled but comes at the cost of converting the native database syntax, e.g. conversion between GEO and ArrayExpress is a non-trivial exercise.
A second barrier to the adoption of standards in genomics for reporting experimental results has been that standards implemented in tools such as MAGE-TAB support only description of the experimental context but often do not include sufficient details for reporting experimental results nor the statistical algorithms and parameters used in its analysis. These are increasingly relevant for an accurate interpretation of the results as they enhance provenance information pertaining to the data transformation process and quality control. Even when this information is available in the models, its inclusion in tools and databases is not always straightforward. For example, in the light of recent additions to standard models, it is now possible to report 'p-value' and 'q-value', however, MIAME based tools do not capture this information since relevant statistical measurements to be reported must often be decided ad hoc, according to the experimental setup and the method used to analyse the data, making genomics experimental context and its results challenging to standardize and integrate. As a result, experimental results are typically reported in the format of MS excel spread-sheets or as journals supplementary material. Connecting experimental context to items of interest in the results, such as drugs, genes, proteins, can also be used to further explore the metabolic processes that explain the phenotype (e.g. multiple genes affected in the same pathway) and to link to results obtained in other ''omics'' sciences. Tools and software that produce/consume experimental results in standardized formats, such as [20] can provide incentives for the adoption of standards by the community.
The promises and challenges of Linked Data and Semantic Web technologies
The introduction of Linked Data and Semantic Web technologies to improve discovery and integrate datasets from many different types of biological domains and from multiples sources has renewed the standardization debate [21] [22] [23] . According to [24] the term Linked Data refers to a set of best practices for publishing and connecting structured data on the Web. Semantic Web, as defined in [25] refers to an extension of the current Web in which information is given well-defined meaning by relying on a stack of technologies, e.g. the resource description framework (RDF), the web ontology language (OWL) and the Sparql Protocol and RDF Query Language (SPARQL), for describing and linking data. By reusing concepts, properties and instance identifiers defined as ontologies when describing and publishing biological datasets as Linked Data, multiple genomics data sources can be more easily integrated [26] .
Agreement on standards is particularly important in Semantic Web queries as they ensure that the effort of converting data to a semantic format such as the RDF is not lost. The urgency to share and reuse ontologies has led to the creation of community portals, such as Bioportal [27] from the National Center for Biomedical Ontology, where biomedical ontologies can be easily shared, anno-tated and searched. Increasingly, tools such as Google Refine's RDF extension, the IO Informatics Sentient Knowledge Explorer and Drupal 7 support for RDF [28] are facilitating and encouraging the reuse of standards and terminologies via plugins that help define a schema when storing the data, thus facilitating the standardized representation for new experimental datasets.
Yet, the data integration problem in biology remains. Using tools such as Drupal RDF extension to integrate datasets already published as Linked Data requires extensive mapping efforts and the overlapping coverage of many ontologies is quickly becoming an obstacle to integrative ''-omic'' sciences today: a basic search for ontologies that include the term ''Gene'' in Bioportal results in 42 ontologies.
Whereas the creation and adoption of semantic standards has accelerated the proposal of new candidate standards, the rate of standardization and agreement on best practices that make use of the standards has lagged behind the development of new methodologies for measuring and annotating biological entities. On the one hand, those publishing Linked Data will often choose those concepts and properties suggested by the data which are most useful to address a problem at hand. On the other hand, many use cases do not yet have appropriate models to represent and thoroughly annotate experimental results. Upper ontologies and ontology alignment can fill a gap in the existing knowledge integration by enabling a posteriori integration, i.e. if two competing ontologies are describing the same concept, they are matched using owl:equivalentClass or the simple knowledge organization system (SKOS) [29] . The Ontology for Biomedical Investigations (OBIs) is in that respect exemplar as it was devised from the bottom-up using terms submitted from various communities [30] . OBI represents a point of accretion for representing experimental processes under the Basic Formal Ontology framework and has become the reference resource bringing together more than 15 communities, serving as basis for application ontologies such as the Experimental Factor Ontology (EFO), an application ontology focusing on experimental variables. The Open Biological and Biomedical (OBO) Foundry has attempted to unify many biomedical ontologies and, by doing so, provides an umbrella for well-structured artefacts relying on a common set of relations and, for some resources, a common top-level ontology [31] .
The emergence of new high-throughput technologies and its standardization should not, ideally, affect the integration of its results with datasets already published as Linked Data. The gap between the aligned ontologies and the datasets that use it is still too wide to enable immediate integration of datasets, particularly in the microarray domains, where the interested communities have not yet agreed on a single ontology to use (e.g. EFO vs MGED Ontology [32] ). Performing integrated queries over such datasets still requires ontology alignment, data transformation and matching of biological entities to support integration of their contents. Our solution to this gap between the need to enable integration of datasets, even when accepted standards do not yet exist or different ontologies were used to annotate and describe it, is to rely on enabling a posteriori data integration: using rule-based query and data transformation, we will illustrate how three datasets using different representation strategies for exposing microarray results as SPARQL endpoints can be integrated. We also provide a web application, available at http://ui.genexpressfusion.googlecode.com/hg/index.html, with demo queries and query transformation. Related work using such approaches for data integration include WikiGenes [33] , WikiPathways [34] or the Linked Open Drug Data cloud [35] .
Methodology
The standard format for publishing Linked Data is RDF, a simple data representation whereby links between entities are represented as triple elements. Consider, for example, the RDF triple [geneid:261729 rdfs:label ''STEAP2''], where geneid:261729 corresponds to the universal resource identifier (URI) for a gene labelled ''STEAP2''. Since the label ''STEAP2'' may be applicable to many types of entities, it is useful to also assert that geneid:261729 is of type dbpedia:Gene by creating the assertion [geneid:261729 rdf:type dbpedia:Gene]. SPARQL is the standard query language for RDF and relies on building patterns that match RDF triples. Using the example above, the SPARQL query for matching all entities of type dbpedia:Gene could be assembled as ''select Ã where {?gene rdf:type dbpedia:Gene}''. In this section we will describe our methodology for assembling SPARQL queries that integrate data from multiple SPARQL endpoints containing genomics results, even when the same data types (e.g. dbpedia:Gene) are not reused. Our methodology relies on two standardized SPARQL 1.1 elements: CONSTRUCT and SERVICE. We will describe the formalisms used in our approach for the integration of heterogeneous datasets and apply it to datasets containing heterogeneous data about microarray experimental results.
RDF approaches to describe microarray experiment and gene lists
Diseases phenotypes such as, e.g. tumours, are often caused by over-expressed or under-expressed genes. A significant number of the experimental studies devised to discover such genes currently rely on microarray technology to simultaneously measure the expression of thousands of genes in relation to a phenotype. Such datasets are often made available on the Web and already account for a large proportion of published available bioinformatics data with over 23,000 experiments shared in ArrayExpress and over 24,000 series in GEO. To accurately represent the relationships between a phenotype and a list of correlated genes, and to integrate it with other related studies, it is necessary to capture the information pertaining both to the list of genes and the experimental context.
To accurately capture the steps that lead to a list of differentially expressed genes, there are several layers of representation that need to be taken into consideration (see Fig. 1 ). The first step (1) captures data about the original sample and where they were extracted from. The second step pertains to the description of the experimental design (2), which include information such as the microarray platform used. The third step (3) pertains to the results themselves, which in the case of microarrays are typically a list of genes that are differentially expressed in normal vs disease samples and associated expression measurements. Statistical processing to go from step 2 to step 3 involves image processing on large files (>100 Mb) where the intensity values for each gene in each sample are recorded; normalization of the results to remove background noise (data processing); and significance analysis and quality control to determine which genes are above a certain threshold to be considered over or under-expressed. This separation of microarray experiment metadata into provenance layers is more thoroughly explored in [36] .
Three different SPARQL endpoints exposing datasets containing high throughput experiment results were used: a. RDF representation of gene lists from the Gene Expression Atlas (GXA) SPARQL endpoint at http://www.ebi.ac.uk/microarray-srv/ openrdf-sesame/repositories/gxa b. RDF representation of Provenance of Microarray Experiments by the W3C BioRDF task force -SPARQL endpoint at http://hcls.deri.org:8080/openrdfsesame/repositories/biordfmicroarray
Gene Expression Atlas
The Gene Expression Atlas (GXA) at the European Bioinformatics Institute (EBI) is an added value database derived from experiments in ArrayExpress which provides summary information about genes and how they are expressed in various experimental conditions [37] . Whereas ArrayExpress contains information about the experimental context of microarray experiments (steps 1 and 2 in Fig. 1 ), GXA functions as a repository of lists of differentially expressed genes associated with those experiments through an accession number (step 3 in Fig. 1) . A team at EBI has created an RDF representation of GXA by reusing EFO concepts and properties, which is made available as a SPARQL endpoint. The RDF schema is illustrated in Fig. 2 -triples were generated using a custom Extensible Stylesheet Language Transformations transform applied to the XML REST output of GXA REST queries for all available experiments. As the ontology imports from various reference ontologies, a number of the classes and predicates shown appear with original URIs (and not EFO URIs). Currently, the GXA SPARQL endpoint represents relationships between an experiment, up to the top 500 differentially expressed genes in that experiment, organism, disease (where applicable), and p-values, among others.
BioRDF Provenance of Microarray Experiments
As part of an effort by the World Wide Web consortium health care and life sciences (W3C HCLS) interest group, three heterogeneous microarray result datasets for detecting biomarkers in Alzheimer's Disease were retrieved from the literature and integrated into a single representation (see Fig. 3 ). These were then used to explore the relevant properties for provenance and replication of the experiments. The ontology was devised using a bottomup approach to enable easy use and adoption and appropriate links were established to reference ontologies such as the software ontology (SWO), the vocabulary of interlinked datasets [38] , the disease ontology, the provenance ontology and the Neurolex Lexicon. This representation of microarray experiment can be further explored in [36] .
HSCI blood genomics dataset
The HSCI blood genomics is a repository of genomics experiments done on hematopoietic stem cells. The repository is currently comprised of highly curated data from gene expression, epigenetic modification, and transcription factor binding studies that have been generated from a variety of technologies and platforms such as microarray and ChIP-Seq. The data is available as Linked Data and a SPARQL endpoint (see Fig. 4 ). The Ontology for Biomedical Investigations (OBIs), Experiment Factor Ontology (EFO) and the MGED Ontology (MO) were used to map the various classes.
SPARQL binding and federation
We illustrate here several design patterns that were used to devise the rule templates useful for integrating genomics datasets. These patterns enable transforming each of the three graphs above into a common, comparable graph definition.
Constructs for class and property mapping
The SPARQL query specification [39] describes the result of a ''construct'' as an RDF graph formed by taking each query solution in the solution sequence and substituting for the variables in the graph template. Effectively, a CONSTRUCT is a template for building graphs that can be queried using specific query formalism. The grammar rule defined for the CONSTRUCT is as follows:
DatasetClauseÃ WhereClause SolutionModifier The ConstructTemplate specifies a template for the query. Construct creates a new graph based on a set of rules that manipulate the shape of the original graph. For example, a construct can be used to map all instances of a class A to instances of a class B. The rules used in the construct contain a rule head, R.h, specifying the ConstructTemplate that will define the shape of the query; and a rule body, R.b specifying the transformation rules that should be applied in the graph (G) to generate the new graph (G 0 )
Modify is the operator applied by a SolutionModifier such as ordering or limiting the results in its tabular representation and therefore will not affect the topology of the graph. To assemble a construct, it becomes necessary to identify which changes in the topology will be necessary to produce the new graph. Consider a substitution of node A with node B; I a is the set of incoming links for A and O a is the set of outgoing links for A. A substitution in graph G to produce graph G 0 would therefore be instantiated as
, where M can be read as ''is mapped to''.
As an example, consider the following template for a query to enable the mapping of all the entities of type ''experiment'' in SPARQL endpoint c) -we wish to use in our query the Experimental Factor Ontology to describe the class experiment. The template or rule head is assembled in the ''construct'' portion of a query:
CONSTRUCT {?experiment rdf:type <http://www.ebi.ac.
uk/efo/EFO_0004033>.} The SPARQL endpoint supporting the blood genomics experiments (c), however, makes use of the MGED ontology ''BioAssay'' to classify entities of type experiment (<http://mged.sourceforge.net/ontologies/MGEDontology.php#BioAssay>). As such, the query template above needs to be instantiated by using the following pattern in the rule body: 
Constructs for URI mapping
It is not uncommon for different URIs to be used when describing the same entity in two different datasets. Unlike class and property substitution, URI mapping relies on the properties of the knowledge domain. This problem can be overcome by creating rules that ensure that the URIs are mapped appropriately between datasets as, in many cases, label matching is often not enough to create enough relevant, reliable links. This is a very common problem in biology, as different datasets tend to use alternative identifiers for the same genes (e.g. Entrez gene ids vs Ensembl gene ids). Consider one such case, where one dataset identifies gene E using Entrez gene id and another dataset identified gene E using probesets (Affymetrix identifiers for short DNA sequences designed to match parts of the sequence of known genes). A solution can be applied that relies on common properties -it can be assumed, in some cases, that two entities sharing the same value for a property, or for a set of properties, can be said to be the same. Consider X and Y to be nodes; {P1, . . . , Pn} to be arcs in the same graph and {a, . . . , z} to be literals or nodes. In summary, given that probe sets are uniquely mapped to a single gene, they can be used to map different gene URI.
Constructs for transforming and replacing values
One final construct pattern that we will introduce is the transformation and replacement of statement values. It may happen, when data has different sources, that the same properties are annotated to different data types with similar meaning. These values can be mapped based on constraints. 
Service
The ''service'' keyword is the final component required to enable integration of distributed datasets. Whereas construct can be used for performing operations in graphs and transforming them to a format that can be queried together, SERVICE is necessary to enable merging graphs available in different URL locations. SERVICE was introduced in SPARQL 1.1 as a means to provide federated query support. Its mechanism relies on sending constrained queries to remote query services. The solution graph results are integrated with the rest of the SPARQL query. The grammar rule for Service is:
In this case, the graph resides in a remote service (S) where the solution to the query (Q) is found. Note that multiple services can be invoked in the same query and also that the local graph store results can be used in a single query. As such, a more generic solution for Eq. (1) In fact, for the graph transformation derived from querying the services (D), it is of little consequence whether the graphs are stored locally and accessed using ''GRAPH'' or remotely and accessed using ''SERVICE''. The goal of the algorithm is to calculate Q1 and Q2 such that:
For example, the ''service'' tag can be used to remotely query the blood genomics SPARQL endpoint: 
A scalable architecture for semantic integration of gene expression datasets
We have used SWObjects [40] , a generic SPARQL engine supporting SPARQL federation and Query transformation using Rules, made available to SWobjects through maps (see Fig. 5 ). Maps are intermediate instructions including the ''CONSTRUCT'' templates that are used to translate a SPARQL query into a format acceptable when querying a secondary source where the data model is not the same. Templating requires transformation of the query so that it uses the classes, and properties, that the remote endpoint can understand. Furthermore, templating can also be used to specify which SPARQL endpoint should be queried for a specific pattern or how the results should be transformed or mapped to maintain consistency. ARQ, a query engine for Jena and TopBraid composer can also be used to assemble the CONSTRUCT queries for a single graph. Maps used in the transformations described are available at http:// code.google.com/p/genexpressfusion/ along with documentationmapping files are kept in a distributed version control system, which will continue to be updated to include new rule mapping as novel functional genomics SPARQL endpoints are made available to the biomedical informatics community or in case the representation of the described SPARQL endpoints changes. Users can either choose to keep their local representations synchronized with our latest version or keep their own version of the mapping files. We have made available a simple web application at http://ui.genexpress fusion.googlecode.com/hg/index.html that can be used to create rule templates based on any SPARQL endpoints that the user wishes to use. Included in the web application is also a series of SPARQL queries integrated over the three SPARQL endpoints described.
Note that, in the process of mapping URI, SPARQL services beyond the scope of the ones described can be used to provide a look-up service. For example, to find the correspondence between probe sets, provided by the BioRDF endpoint (b) and Ensembl gene identifiers, provided by the GXA endpoint (a), the Bio2RDF Affymetrix SPARQL endpoint (http://affymetrix.bio2rdf.org/sparql) can be used as a look-up service. Furthermore, labels for many of the URI available through the blood genomic endpoint (c), can be retrieved from the neurocommons SPARQL endpoint (http://sparql.obo.neurocommons.org/sparql). This architecture enables, for example, querying the blood genomics endpoint for all datasets that were performed on ''Homo sapiens'' samples, even when the actual label does not exist in the endpoint. In the current implementation, remote SPARQL endpoints used as look up services were saved as graphs to accelerate queries as these datasets are unlikely to often change.
Results
CONSTRUCT and SERVICE were used in combination for dealing with three heterogeneous (differently represented) and distributed (available in multiple locations) data sources. In this section, we will illustrate some of the query patterns and transformation rules and how they are applied in the integration of the three microarray experiment datasets.
Challenge 1: To answer the same competency questions from each of the endpoints, the syntax of the SPARQL queries are necessarily different.
As To solve and align these three we have prepared a table with the equivalent classes and properties between the three representations (see Table 1 ). We have mapped endpoints (b and c) to match the ontology descriptors in (a).
Solution to challenge 1: We make use of the construct operation defined in Eq. (1) for this purpose and the service inclusion specified in Eq. (4) In the rule template above, information about samples used to perform the experiment is not directly associated to an experiment, but, instead, is represented using mged:BioMaterial as suggested by the MAGE standards. To maintain consistency with the description of the model organism used in the experiments described in the other two endpoints (a and b), a label for taxon is retrieved from a remote endpoint as it does not exist in the original dataset. Furthermore, the blood genomics endpoint does not yet include the experimental results in the form of result sets of gene lists. This should not affect the query, as it is possible to use the ''optional'' keyword to return experiments, whether they contain result sets or not.
Including the mapping files above in a SPARQL 1.1. engine supporting rule templates enables data to be collected from all three datasets using EFO and OBI: The query above (corresponding to Q3 in our web application) returns all instances of microarray experiments in the three included datasets graphs, and their experimental contexts, regardless of the terms or topology of the ontology used to annotate and describe them. Note that this query can be directly performed in the GXA SPARQL endpoint (a) and therefore a rule template is not required. The OPTIONAL keyword allows for experiments to be matched even when there are no results associated, as was the case for the bloodgenomics endpoint (c).
Challenge 2: A recurrent problem in bioinformatics applications is the use of different gene identifiers to refer to the same genes. This was the case for endpoints (a and b): whereas in (a) Ensembl identifiers are used, in b) results of microarray experiments are mapped to Affymetrix probesets. As such, discovering the genes that match across the datasets will rely on a external source (http://affymetrix.bio2rdf.org/sparql) where probe_ids are first transformed to Ensembl gene ids.
Solution to challenge 2: We make use of the construct operation defined in equation 2 for mapping genes based on their properties as well as the service inclusion specified in equation 4. To achieve the mapping between two types of gene identifiers, the probe_ids in the bioRDF endpoint (e.g. 225871_at) are first transformed into URIs that can be queried in the affymetrix SPARQL endpoint (e.g. http://bio2rdf.org/affymetrix:225871_at). The result of that query is a list of the corresponding ensemble gene identifiers formatted as bio2rdf URIs (e.g. http://bio2rdf.org/ensembl:ENS-MUSG00000037916). Since the GXA endpoint makes use of URL for ensembl identifiers in the form http://ensembl.org/Gene/Summary?g=ENSMUSG00000037916, rather than the bio2rdf URI used by affymetrix, these need to be further transformed using substring and concatenate functions to enable mapping. The above rule template will enable querying genes by its Ensembl identifiers even if these were not specified in the source dataset (b). The following query (Q1 in our web application) will return all entities of type gene by referring to their Ensembl identifiers in both datasets (a and b):
PREFIX gene: <http://www.ebi.ac.uk/efo/ EFO_0002606> SELECT ⁄ WHERE { ?gene a gene: } Challenge 3: When considering gene expression results, there are two ways to report the data: in the first case, gene expression can be defined to be ''UP'' or ''DOWN'' (non-differentially expressed genes are not included in this dataset). These values, however, are inferred from the actual experimental results, where the data is numerical: in the second case, the fold change, i.e. the amount by which the expression of the gene increases in the disease vs the normal case, can be used to express gene expression results. In such cases, values of fold change >0 must be mapped to ''UP'' whereas those where fold change <0 can be mapped to ''DOWN''. These two representations clearly have different granularity.
Solution to challenge 3: We make use of the construct operation defined in equation 3 for binding expression based on differential fold change values: 
In the rule template above, numeric values of foldChange are converted into the value ''UP'' when differentially expression is assessed to be above zero and as ''DOWN'' when they are assessed to be below zero. The results from the integrated queries above are made available for inspection at http://www.ui.genexpressfusion.googlecode.com/hg/index.html#demo.
A use case scenario for gene expression scientists
To illustrate how our method can be used for enabling discovery in life sciences, consider the following scenario: a researcher wants to find whether NADH dehydrogenase (ENSMUSG00000037916) is over expressed (''UP'') in the heart. He also wants to discover, in the same experiments, which other genes are co-upregulated and what is their function in the cell by searching gene ontology (GO), as this may indicate protein-protein interactions that can be explored for drug discovery. As illustrated in Figs. 2-4 , the topology of the graphs containing the experimental context may be different even when standards terminologies are reused, forcing the researcher to assemble multiple SPARQL queries to retrieve expression values for this gene across experiments where ''cardiac gene expression'' is measured. Using the method described, the query can be issued using standard EFO and OBI terms, and the rule maps will ensure that it is appropriately translated into multiple SPARQL endpoints. Furthermore, the gene ontology term corresponding to the other genes of interest can be retrieved with the same query using the SERVICE tag to retrieve the GO URI (e.g. <http://bio2rdf.org/ go:0005216>) first from the affymetrix SPARQL endpoint and use that information to query the GO SPARQL endpoint in order to retrieve a definition related to those GO URI (e.g. ''ion channel activity''). The following query could be used with this purpose: 
Methodological contribution
The work presented here is a reflection of the need to compromise between enabling integration of life sciences datasets in a single format, and the limitations imposed by large datasets. Given the size of each of the genomics datasets presented, it would not be feasible to integrate all the necessary triples into a single triple store. As such, the SERVICE functionality supporting SPARQL federation is a key element (see Fig. 5 ). The different representations used to categorize and organize the data reflect the division in the community regarding the adoption of standards. Rather than imposing or suggesting a new standard, our approach relies on transforming a set of queries into a single format, created as a template from the largest of the three endpoints -the GXA.
In this report we address how experimental results reported in heterogeneous datasets could be integrated using a set of integration techniques that we are classifying as a posteriori. These techniques assume that the engine responsible for the integration has read-only access and cannot modify the source datasets to ensure proper annotation of its content. As such, integration engines using this methodology do not assume that datasets use ontologies to annotate their content, but make use of them when they exist. In order to achieve integration between three genomic datasets, we devised rule templates to map, transform and reconcile queries and data. The integration method proposed relied on the following steps: (1) When the datasets did not reuse ontological concepts, the topology of the graph was aligned for instances representing similar entities, annotated with different ontologies, (e.g. experiments and their contextual description) to be captured in a single intuitive query, (2) URIs were matched by creating link specifications targeting unique properties of the entities (e.g. the probeset identifiers were used to map gene to Ensembl identifiers) and (3) data values were transformed to be made comparable (e.g. foldChange > 0 were transformed to the value ''UP'').
Discussion
Integration of experimental context and results from functional genomics studies is a core requirement both for the discovery of novel biological interactions and for translational research. Although there have been significant advancements in integrative technologies over the past few years, particularly by making use of Semantic Web and Linked Data technologies to integrate health care and life sciences datasets [41] , choosing vocabularies, ontologies and lexicons to use when representing raw experimental datasets in the Web of Linked Data is still an area of much debate. As a result, different publishers of ''-omics'' experimental results end up using different ontologies and terminologies to describe their datasets, even when their content is very similar. This in itself is not problematic, as integration of datasets in the Semantic Web can be achieved with a priori solutions -by aligning the ontologies and using them to recreate the dataset -or a posteriori solutions -using information about the existing representation in the datasets to create rule templates, query transformation rules that will enabled standardized access to different datasets, even if they were represented using different ontologies. There are three generic strategies that can be used for integration of Linked Data:
(1) Community acceptance of a standard (e.g. MAGE-TAB) that is reused to represent similar data in different SPARQL endpoints; (2) Making use the first order logic enabled by RDFS/OWL to merge classes and properties from multiple ontologies under a single ontology; (3) Using rule templates that map the topology and entities in the native ontologies and transform the value of statements based on some transformation rules.
A priori solutions such as (1) make sense when there are few instances of a data type or no instances at all. Such an approach requires community agreement ''before'' data is published as Linked Data. However, forming community consensus on a standard representation can be difficult. Moreover, waiting for a community standard to be developed and accepted could indeed be detrimental in the short term as it would delay the publication of datasets as Linked Data. A posteriori solutions such as (2) and (3) are favoured by Semantic Web technologies as these include mechanisms to describe two classes, for example describing experiments, to be said to be ''the same''. When strategy (2) is used, reasoning engines can be put to use to infer the appropriate equivalence statements which enable queries to be executed on datasets using different ontologies and terminologies. However, reasoning is expensive -particularly when the datasets include a large number of instances but a small number of classes. As an alternative, the rule templates proposed in strategy (3) can be used as a light-weight, simple mechanism to mask the differences in the datasets representation and enable integrated queries. In fact, rule templates are the appropriate option for datasets that include a small number of classes and relationships but a large number of instances with very heterogeneous statement values or objects, as was the case with the three transcriptomic datasets described. The result of these transformations can be saved as named graphs such that they can be quickly re-queried later.
Foundations for a generic integrative bioinformatics solution
The three SPARQL endpoints described contained similar content without entirely overlapping -the blood genomics dataset, for example, does not yet include the list of genes derived from the statistical treatment of the experimental results but, on the other hand, does provide linking to the original raw data files. Similarly, the bioRDF example includes information about the probes that were used in the microarray design. Experimental context for this dataset was collected from the publications where they were first reported, and the software used to process the raw data has been included. The GXA is the most comprehensive of the datasets but, due to its close relationship to ArrayExpress, the details about experimental context and links to raw experimental files are delegated to the upcoming publication of ArrayExpress as Linked Data. Once a SPARQL endpoint for ArrayExpress is made available, SPARQL federation will enable complementing our rule templates with the experimental context details for the GXA. In fact, because this method enables synchronization of the mapping files to a central repository at code.google.com, users of our system will need only to synchronize their files to the latest version to start querying the data with the new mappings immediately. We know, for example, that MGED ontology is being replaced by OBI. Mapping can be kept synchronized with these changes, and be made immediately available to the users. Furthermore, because we are using a controlled versioning system, it is possible to keep track of changes and to make them available as a SPARQL endpoint.
Encouraging reuse of biomedical ontologies
Widespread usage of the web application supporting this report could reveal the patterns (or collection of patterns) that are most useful and intuitive to its users. This can potentially be applied in improvements to current biomedical ontologies to reflect those patterns. Using rule templates, the complexity of the queries necessary to retrieve and link data from heterogeneous SPARQL endpoints can be masked such that the query itself can be made more intuitive without effecting interoperability of the datasets. Rule templating based on biomedical ontologies enables a fine grained control in ontology alignment and the possibility of staying current with the latest developments in ontology identification. Rule templates can also be easily extended to include other parameters such as the functional roles of the genes by retrieving gene ontology terms or the chromosome position, as illustrated in one of the demo queries in our web application (Q7), without the data actually existing in any of the three included datasets. In fact, one of the most promising outcomes of publishing lists of genes derived from microarray experiments as Linked Data is the possibility to enable the discovery of almost any relationship between the differentially expressed genes such as, e.g. that their protein products are involved in the same or related pathway or to discover compatible drugs using pharmacogenomics.
It is worth noting that, in our methodology, we do not create a new representation of the data in the assembly of the construct templates but, instead, assemble templates that are executable in one of the endpoints -the GXA, the largest one supporting EFO and OBI -and serialize that representation into a rule template that can be used to consistently transform results from the other endpoints. Publishers of microarray-based transcriptomic experimental results are still free to select the ontologies and terminologies that they find more intuitive and create rule templates to enable integrated queries; if they do use EFO and OBI, however, query federation with the three datasets mentioned is immediate.
SPARQL and the health care and life sciences communities
SPARQL is a new technology and, as with every new technology, there is a learning curve that will prevent immediate adoption by health care and life science communities. Agreement on a standardized method to view and access the data enables the development of domain specific languages that simplify and generalize most of the details involved in assembling semantic queries. While attempting integration at a single store is not feasible owing to the large size of microarray datasets, the seducing solution of query federation has drawbacks too, ranging from timeout during query execution and variation in behaviour of individual nodes [42] . Mechanisms to deal with this bottleneck are not yet in place. However, the ability to construct and save graphs that serve as temporary representations of the remote endpoints may provide a feasible intermediate solution. Furthermore, as more and new SPARQL endpoints publish ''-omics'' studies and their results are added to the Linked Data Web (e.g. the ISA-TAB formatted innomed dataset [43] [44] [45] currently hosted by the BioInvestigation Index [46] ), the queries necessary to integrate them will likely increase in complexity, involving multiple service calls and constructs for transformation. Masking such complexity with rule templates is a stepping stone for improving adoption of Semantic Web and Linked Data technologies by the health care and life sciences communities.
Conclusions
There is still a wide gap in our ability to use Linked Data and Semantic Web technologies to address the integration of life sciences datasets. The promise of improving translational research and enabling patient-oriented pharmacogenomics motivates solutions for addressing this gap. The proliferation of bio-ontologies in BioPortal suggests that rich descriptions of data have become important to the HCLS community, but may also be an indication that more tools are needed to encourage the application of existing ontologies, as opposed to designing new ones. We have identified a set of patterns appropriate for transforming queries into a format acceptable to federated SPARQL endpoints holding microarraybased functional genomics experimental results. This strategy is effective at integrating datasets with a large number of instances but small number of classes and properties. A key characteristic of our approach is that we do not try to improve on the expressivity of existing Semantic Web standards for functional genomics, which are already abundant but, instead, ensure that existing datasets published from transcriptomic experiments can be queried together with minimal effort from the data publishers. It is possible that, as a result of our work, the existing datasets are updated to be compliant with EFO and OBI. However, this will not affect our queries since those are the templates used by default. If, instead, the data publishers decide to use another ontology not contemplated in our methodology, the updated rule template files can be synchronized with a version control system. In fact, this can become a powerful method to enable the emergence of universal domain specific languages for genomics by relying on simplified SPARQL. 
